{"id":"46063","type":"article","url":"https://hartvaat.nl/2026/04/12/lipidenmanagement-bij-type-2-diabetes-richt-je-op-alle-atherogene-lipoproteinen-/","title":"Lipidenmanagement bij type 2-diabetes: richt je op álle atherogene lipoproteïnen (non-HDL-cholesterol)","title_en":"Lipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Cardiovascular diabetology","doi":"10.1186/s12933-026-03166-4","source_url":"https://doi.org/10.1186/s12933-026-03166-4","authors":["Julia Brandts","Marlo Verket","Alberto Zambon","Nikolaus Marx","Dirk Müller-Wieland","Massimo Federici"],"significance":6,"published":"2026-07-19","source_date":"2026-04-12","image":"https://hartvaat.nl/global/img/cccce4a31502.webp","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenverlaging-stappenplan/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality in diabetes, partly driven by dyslipidaemia. Although LDL cholesterol (LDL-C) is the primary treatment target, many patients with diabetes have mixed dyslipidaemia with elevated triglycerides and atherogenic remnant lipoproteins, better captured by non-HDL cholesterol (non-HDL-C). Guidelines from the ADA, AACE and ESC recommend both LDL-C and non-HDL-C targets based on individual risk, yet target attainment remains suboptimal in practice. Statins, ezetimibe, bempedoic acid and PCSK9 inhibitors effectively lower LDL-C and non-HDL-C and reduce cardiovascular risk; triglyceride-lowering agents (omega-3, fibrates) lower triglycerides but their effect on hard outcomes remains uncertain. This review argues for using non-HDL-C and apolipoprotein B (apoB) alongside LDL-C as measures of atherogenic burden, and for more targeted treatment of residual atherogenic particles in diabetes.","created":"2026-07-03T20:27:13Z","updated":"2026-07-04T19:26:56Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Atherosclerotische hart- en vaatziekten (ASCVD) blijven een belangrijke oorzaak van ziekte en sterfte bij diabetes, deels door dyslipidemie. Hoewel LDL-cholesterol (LDL-C) het primaire behandeldoel is, hebben veel patiënten met diabetes een gemengde dyslipidemie met verhoogde triglyceriden en atherogene remnant-lipoproteïnen, die beter worden weergegeven door het non-HDL-cholesterol (non-HDL-C). Richtlijnen van ADA, AACE en ESC adviseren LDL-C- én non-HDL-C-doelen op basis van het individuele risico, maar het halen van deze doelen blijft in de praktijk suboptimaal. Statines, ezetimibe, bempedoïnezuur en PCSK9-remmers verlagen LDL-C en non-HDL-C effectief en verminderen het cardiovasculaire risico; triglyceridenverlagers (omega-3, fibraten) verlagen wel de triglyceriden, maar hun effect op harde uitkomsten blijft onzeker. Dit overzicht pleit ervoor om naast LDL-C ook non-HDL-C en apolipoproteïne B (apoB) te gebruiken als maat voor de atherogene last, en om de resterende atherogene deeltjes bij diabetes gerichter te behandelen.","abstract_original":"Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality in individuals with diabetes, partly driven by dyslipidemia. While low-density lipoprotein cholesterol (LDL-C) reduction is the primary target of lipid management, many patients with diabetes exhibit mixed dyslipidemia characterised by elevated triglycerides and increased concentrations of atherogenic remnant lipoproteins, which are more comprehensively captured by non-high-density lipoprotein cholesterol (non-HDL-C). Current guidelines from international societies, including the American Diabetes Association (ADA), the American Association of Clinical Endocrinology (AACE), and the European Society of Cardiology (ESC), recommend LDL-C and non-HDL-C targets based on individual cardiovascular risk profiles. Despite clear therapeutic algorithms, lipid target attainment remains suboptimal in routine clinical practice, necessitating more intensive and individualised treatment strategies. Lipid-lowering therapies, including statins, ezetimibe, bempedoic acid and PCSK9 inhibitors, effectively reduce LDL-C and non-HDL-C, significantly lowering cardiovascular risk. Triglyceride-lowering therapies, including omega-3 fatty acids and fibrates, have demonstrated substantial reductions in triglyceride levels, but their impact on cardiovascular outcomes remains uncertain. Given the heterogeneity of dyslipidemia in diabetes, non-HDL-C and apolipoprotein B (apoB) have emerged as superior markers for assessing atherogenic burden. While LDL-C reduction remains central, additional efforts are needed to optimise the management of residual atherogenic lipoprotein particles in diabetes. Future research should focus on refining risk stratification, improving lipid target attainment, and integrating novel lipid-modifying agents to enhance cardiovascular outcomes in this high-risk population."}